Quantcast

Latest Sorrento Stories

2014-03-11 08:28:30

SAN DIEGO, March 11, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran Mark W. Durand to its Board of Directors. Mr. Durand has nearly 28 years of broad pharmaceutical industry experience in a variety of leadership roles for both branded and generic drugs. Currently, Mr. Durand is an independent strategic...

2014-03-06 08:29:57

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the ROTH Capital Partners 26(th) Annual Growth Stock Conference. The presentation will take place at noon PDT on Tuesday, March 11, in Salon 5 of the Ritz Carlton in Dana Point, Calif. A live...

2014-03-06 08:29:53

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present a comparison of the pharmacokinetic (PK) properties of Cynviloq and nab-paclitaxel (Abraxane(®)) at the 31(st )Annual Miami Breast Cancer Conference in Miami Beach, Florida. Highlights of the findings include new and historical data on PK bioequivalence of...

2014-03-03 08:30:21

SAN DIEGO, March 3, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of anesthesiologist and pain specialist, Mike Royal, M.D., JD and MBA. He was most recently Chief of Clinical Affairs at AcelRx. "Mike's expertise in drug development and pain management is exceptional and key to our success in advancing our clinical pipeline," said...

2014-02-10 16:26:58

SAN DIEGO, Feb. 10, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today the Company has obtained exclusive rights to Cynviloq(TM) (marketed as Genexol-PM(®) in South Korea and other countries) in Australia, Canada and Mexico from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation. Sorrento already has exclusive rights from Samyang for...

2014-02-06 08:28:24

SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, will present at the 16(th) Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10 -11 at...

2014-02-03 08:26:48

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation. "Daniel's proven expertise overseeing the successful development of major oncology...

2014-01-10 12:25:56

SAN DIEGO, Jan. 10, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com) announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, will present a corporate overview at the following events next week in San Francisco: Event: Biotech Showcase 2014 When: Monday, January 13, 2014 at 3:00 PM PT Parc 55 Wyndham San...

2014-01-09 08:28:57

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran William Marth, as Chairman of the Board of Directors. Mr. Marth was the President and CEO of Teva - Americas until the end of 2012, and served as a senior advisor to Teva Pharmaceuticals until the end of 2013. During his tenure at Teva -...

2014-01-08 08:29:26

SAN DIEGO, Jan. 8, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the appointment of Amar Singh as Executive Vice President and Chief Business Officer. In this role, Mr. Singh will be responsible for overseeing Sorrento's partnering activities. He brings over 25 years of experience in business and commercial...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related